The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (10)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
547 result(s) found, displaying 61 to 70
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 40 mg film-coated tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 20 mg film-coated tablet blister pack.
-
Australian Public Assessment Report (AusPAR)AusPAR for Lucentis (ranibizumab) for the treatment of retinopathy of prematurity
-
Designation or determinationOrphan drug
-
Australian Public Assessment Report (AusPAR)AusPAR for JAKAVI (ruxolitinib phosphate) for the treatment of graft-versus-host disease.
-
Australian Public Assessment Report (AusPAR)Scemblix (Asciminib) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukaemia
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd